



Analyst: Neetika Gupta

TAWUNIYA AB , SAR (RHS)

Tawuniya Insurance - 2Q23 Result Review

Target Price (SAR): Previous Recommendation: Accumulate 95.43 TP: SAR 95.43 per share; Accumulate 22-December-2022 Previous Reco. & Date: Upside / (Downside): -33.3% 08-08-2023 Bloomberg Ticker TAWUNIYA AB Current Market Price (SAR) 143.000 1,200 180.060 52wk High / Low (SAR) 162/65 1,000 12m Average Vol. (000) 228 7 Mkt. Cap. (USD/SAR mn) 4,765/17,875 100.060 Shares Outstanding (mn) 125.0 600 80.060 Free Float (%) 74% 60.060 3m Avg Daily Turnover (000) 32,501.8 40.060 6m Avg Daily Turnover (000) 30,319.5 200 20.060 P/E'23e (x) 20.7 0.060 P/Bv'23e (x) Jan-00 Nov-22 2.8 Sep-22 Aug-23 Dividend Yield '23 (%) 1.9% Price Perf. (1m/3m) (%) -7.4/31

Gross Written Premium (GWP) increased 42% YoY, in line with our expectation

Tawuniya reported a 42% YoY growth in GWP for 2Q23, achieving SAR 4,592mn for the quarter. For 1HFY23, GWP grew 45% YoY mainly attributed to 47% YoY growth in 1Q23 as well as growth in 2Q23.

Wolume, '000 (LHS)

Profit before tax grew 212% YoY, in line with our estimates

The company reported a net profit of SAR 275.9mn, in line with our expectations. Profit before tax increased due to an increase in net investment income by SAR 29.67mn during the quarter. For 1HFY23, net profit was up 292% YoY to SAR 377.2mn driven by strong performance in 1Q23 and 2Q23. Profit before tax grew 1201% in 1Q23 as investment income increased by SAR129.26mn.

Maintaining our "Accumulate" rating on the stock

We expect the GWP of the company to grow led by compulsory medical insurance for expat and their families and an increase in construction activities in Saudi Arabia which will benefit the P&C segment. Going ahead, we expect the retention ratio to increase as the company is lowering its ceded premiums for the medical segment. We continue to maintain an "Accumulate" rating on the stock.

Tawuniya is trading at 2023e P/E of 20.7x, representing a 2% premium compared to the historical average P/E of 20.2x. Additionally, P/Bv multiple of 2.8x, based on our FY23 estimate, represents a 6% discount compared to the historical average P/Bv of 2.9x.

| Income Statement | | | | | | | | | | | | | |
|-----------------------|---------|---------|------|------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| (SAR mn) | 1Q22 | 2Q22 | 3Q22 | 4Q22 | 1Q23 | 2Q23 | 2Q23e | YoY (%) | QoQ (%) | Var (%) | 1HFY22 | 1HFY23 | YoY (%) |
| Gross Written Premium | 3,508.7 | 3,224.6 | NM* | NM* | 5,161.1 | 4,592.0 | 4,401.3 | 42% | -11% | 4% | 6,733.3 | 9,753.1 | 45% |
| Profit Before Tax | 7.8 | 88.4 | NM* | NM* | 101.3 | 275.9 | 286.9 | 212% | 172% | -4% | 96.2 | 377.2 | 292% |
| | | | | | | | | | | | | | |

^{*} Company has changed its reporting pattern starting 2023. For Q3FY22 and Q4FY22 we don't have the restated numbers. If we put the old numbers with the restated numbers for Q1FY22 and Q2FY22, the annual figures won't match. Hence we have written NM.

For our earlier report, please click here.





Recommendation

| BUY | Greater than 20% |
|------------|-----------------------|
| ACCUMULATE | Between +10% and +20% |
| HOLD | Between +10% and -10% |
| REDUCE | Between -10% and -20% |
| SELL | Lower than -20% |



Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net
PO Box 1137
PC 111, Sultanate of Oman
Tel: +968 2494 9000
Fax: +968 2494 9099

Email: research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research, and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report, and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.